Skip to main content
OpenTrials
Completed

NCT Number: NCT00971984

Demographic, Clinical and Laboratory Characteristics of Children With Alpha Thalassemia in Northern Israel

The study intends to summarize the clinical and laboratory characteristics of children with hemolytic anemia diagnosed as having alpha thalassemia mutations.

Completed

Looking for future studies?

Notify Me

Key information

Age range

Up to 20 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Pediatric Hematology Unit and Pediatric Dpt B - HaEmek Medical Center

Afula, 18101, Israel

About this study

Fifty children and adolescents diagnosed as having alpha thalassemia will be studied, the clinical characteristics and hematology analysis will be summarized.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All the patients that were studied at the pediatric hematology unit ant the Ha'Emek Medical Center

Exclusion criteria

  • None

Treatment and study plan

Medical records summary

Other

Summary of Medical files and laboratory results.

Primary outcomes

  1. Analysis of the Demographic, Clinical and Laboratory Characteristics of Children With Alpha Thalassemia

    Time frame: One year

    Analysis of the Demographic, Clinical and Laboratory Characteristics of Children With Alpha Thalassemia

Sponsors and collaborators

Lead sponsor

HaEmek Medical Center, Israel

Other

Registry information

Important dates

Study start
2009
Primary completion
2012
Study completion
2012
First posted
Sep 4, 2009
Registry last updated
Sep 1, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.